SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

HSBCs bearish view on CoreWeave has amplified concerns about its debt-heavy data-center expansion, rising financing costs, and potentially slowing AI demand. Traders are split between buying the selloff and anticipating a short squeeze, and warning that credit and insider-selling risks could prolong the decline.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on Middle East supply concerns, including reported tanker and energy-infrastructure attacks, while traders also weigh Ukrainian strikes on Russian oil assets. The community is split between expecting supply risks to keep oil elevated and betting that diplomacy, supply relief, or an overextended rally will bring a pullback.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being tied by traders to weakening confidence in Trump and the approaching midterms, alongside concerns about the companys limited business fundamentals and Truth Social. The discussion is broadly bearish, though some traders view the decline as a possible short-term trading bounce.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A European Medicines Agency committee recommendation for Lillys Foundayo obesity pill is fueling a breakout to fresh highs, with traders also focused on the upcoming earnings report. Bulls see the pill as expanding Lillys obesity-market reach, while skeptics question whether the gains will hold and point to competition from Novo Nordisk.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp, extended semiconductor selloff has put SOXX in focus, with traders debating whether fears over AI spending returns, debt and crowded positioning signal a deeper downturn or an oversold bounce. Some see upcoming chip and hyperscaler earnings as a test of demand and capex, while others remain cautious about the sectors technical weakness.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapport Therapeutics is drawing attention after RAP-219 met the primary and secondary endpoints in a Phase 2 trial for acute bipolar mania. Traders are divided: bulls view the results as proof of concept and note plans for Phase 3, while skeptics question the modest efficacy and point to agitation and discontinuation concerns as the initial rally faded.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 results and outlook are drawing attention, with traders focusing on strong revenue growth, AI-related demand, and recurring royalties from its Vertical Power Delivery licensing business. The reaction is broadly bullish after the shares rise, though some traders question the valuation and weigh the earnings details against capacity constraints and uncertainty around how durable royalty revenue will be.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly results beat expectations and management raised its outlook, but shares fell as traders focused on rising costs, weaker free cash flow, and a loss in the insurance business. Bulls view the selloff as an overreaction to a strong report, while bears point to cost and execution concerns and continued technical weakness.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RKLB Vs ASTS: Bestselling Investing Author Picks The ‘Lottery Ticket’ With Better Odds — But SpaceX Is The ‘Top Dog’ 

Equity

ASTS offers “damn compelling” direct-to-cell potential, but Feroldi warned that “50 things” could go wrong before commercialization.

ASTS Stock Hits One-Month Low: Insider Buys The Dip After BlueBird Deployments, Japan Win 

 Director Adriana Cisneros disclosed 10,822 open-market share purchases worth about $619,200.

One Space Stock Outran SPCX, ASTS, RKLB And LUNR In August — BofA Says It Can Rally Another 30%

BofA retained a ‘Buy’ rating on RKLB with 72% implied upside, but maintained ‘Underperform’ ratings on RDW and LUNR.

ASTS Stock Turns Green After 2-Month Slide: Japan Backs 700 MHz Rakuten-ASTS Network To Rival SpaceX

Japan’s Radio Regulatory Council endorsed the proposed 700 MHz direct-to-smartphone framework, with final regulations expected shortly.

SPCX, ASTS, RKLB And FLY On Watch: Goldman Sachs Sees $1.8 Trillion Space Economy And Rising M&A Wave 

Companies controlling launch and orbital infrastructure could capture “disproportionate value,” the research firm said.

ASTS And RKLB Chase The SpaceX Playbook, But Analyst Flags ‘Very Inflated Valuations’ And Mounting Delays 

Analyst Tim Farrar said Rocket Lab may be better shielded from SpaceX, while AST faces direct competition from Starlink.

ASTS Stock Rises Overnight: AST SpaceMobile Clears The Runway For ‘Imminent’ UK Direct-To-Cell Service With Vodafone

ASTS said carriers “want the service now,” prompting AST SpaceMobile to push hard for a rapid rollout.

ASTS Vs RKLB: The Market Picked One, Cathie Wood Backed The Other — Which Space Play Won Q2?

ARK Invest bought 292,873 Rocket Lab shares worth about $23.43 million across ARKK, ARKQ and ARKX as the stock weakened.

Themes ETF Trust - Leverage Shares 2X Long ASTS Daily ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Feroldi ranked SPCX first, RKLB second and ASTS a “distant third,” suggesting a 75%-25% split favoring RKLB.</li><li>Feroldi praised Rocket Lab CEO Peter Beck as “a five, hands down,” but said “it all comes down to Neutron.”</li><li>Feroldi said ASTS could eventually hit a $100 billion-$200 billion valuation, while SPCX remains the space race’s “top dog.”</li></ul><p>Bestselling investing author Brian Feroldi prefers Rocket Lab (RKLB) over AST SpaceMobile (ASTS), calling both speculative “lottery tickets” but arguing Rocket Lab is further along and offers “better odds.”</p><h2 class="st-heading-2"><strong>RKLB Gets The Edge Over ASTS&nbsp;</strong></h2><p>Feroldi, author of Why Does the Stock Market Go Up? and founder of Long Term Mindset, firmly favored Rocket Lab. “If you’re choosing versus Rocket Lab, definitely Rocket Lab,” he<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=AGNYZw41Z80">&nbsp;said</a>, suggesting a hypothetical 75%-25% allocation in favor of RKLB.</p><p>“It’s a price-to-lottery-ticket,” he said. “This lottery ticket looks to me like it has better odds than the other lottery ticket because it’s further along.” Rocket Lab operates the flight-proven Electron rocket, manufactures spacecraft and components, owns launch infrastructure and serves commercial and government customers. Electron completed its 94th mission on Wednesday, deploying another Synspective Earth-imaging satellite.</p><p>The company reported record second-quarter (Q2) revenue of $234 million, up 62% year-over-year, and has secured major defense opportunities, including the Space Force’s $981 million-ceiling NITE-STAR vehicle, a $266 million HASTE contract and a $397 million satellite build-launch-operate award.</p><p>Feroldi also praised CEO Peter Beck as “a five, hands down” and “a very impressive individual.”&nbsp;</p><h2 class="st-heading-2"><strong>Neutron Remains RKLB’s Biggest Test</strong></h2><p>Neutron, Rocket Lab’s larger reusable rocket under development, is both its biggest catalyst and its greatest risk. “It all comes down to Neutron,” Feroldi said. His reverse-DCF analysis suggested Rocket Lab must grow revenue by 46% annually over the next decade to justify its current valuation, assuming a 15% long-term free-cash-flow margin.&nbsp;</p><p>Beck has said the window for a year-end debut is narrowing, with integrated testing, a wet dress rehearsal and a first-stage static fire still ahead. The first stage is targeted to reach Virginia in the fourth quarter.</p><p>Rocket Lab’s pending $8.1 billion enterprise-value acquisition of Iridium Communications could also reshape the business. Iridium generates $300 million in annual free cash flow, which could broadly offset Rocket Lab’s current losses. “That transaction might move this company to, let’s just call it, break-evenish,” Feroldi said, adding that it could “rocket” the company into a more mature phase while diversifying its revenue.</p><h2 class="st-heading-2"><strong>ASTS Offers ‘Damn Compelling’ Upside&nbsp;</strong></h2><p>Feroldi called AST SpaceMobile’s plan to deliver broadband directly to ordinary phones without special hardware “damn compelling.” AST has partnerships with more than 60 mobile operators covering about 3 billion subscribers, including AT&amp;T, Verizon Communications and Vodafone. BlueBird 12 and 13 recently deployed their arrays, a New Zealand gateway is operational and US Mobile is preparing a fourth-quarter direct-to-cell launch.</p><p>Berenberg initiated ASTS at ‘Buy’ with a $92 target on Wednesday, implying about 50% upside from the mid-$60s and helping lift the shares about 12%.&nbsp;</p><p>“There’s like 50 things that could go wrong with SpaceMobile,” Feroldi cautioned, pointing to launch execution, cash burn, dilution and Starlink competition. Yet, if ASTS succeeds, he said it could resemble “American Tower in space,” potentially supporting 20% to 30% free-cash-flow margins. “If this works, would it be ridiculous to think this is a $100 billion company or a $200 billion company?” Feroldi said. “Probably not.”</p><h2 class="st-heading-2"><strong>SpaceX Is Still The ‘Top Dog’</strong></h2><p>Despite backing RKLB over ASTS, Feroldi placed SpaceX above both due to its scale and first-mover advantage. “Look for the top dog and first mover,” he said. “Who is the top dog and first mover in the space race? SpaceX.” Feroldi said he would consider breaking his usual rule against buying newly listed companies during their first year, though he would prefer SpaceX at a valuation of roughly $600 billion to $800 billion.&nbsp;</p><p>“I would go with SpaceX first, Rocket Lab second, ASTS a distant third,” Feroldi added.&nbsp;</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About ASTS, RKLB And SPCX?</strong></h2><p>On Stocktwits, retail sentiment was ‘bullish’ for ASTS amid ‘high’ message volume, ‘neutral’ for RKLB amid ‘low’ activity, and ‘bearish’ for SPCX amid ‘extremely low’ volume.&nbsp;</p><p>Over the past year, ASTS and RKLB have each gained 28%, while SPCX has fallen 13%.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/nio-geely-chip-push-analyst-calls-shares-undervalued/cZsMmkbRJHn">NIO Stock Could Get Geely Boost As Chip Push Expands Beyond Own EVs — Analyst&nbsp; Calls Shares ‘Undervalued’&nbsp;</a></p>

The Soyuz rocket launches to the International Space Station with Expedition 75 crewmembers: NASA astronaut Anil Menon, Roscosmos cosmonauts Pyotr Dubrov, and Anna Kikina onboard, on July 14, 2026. (Photo by Bill Ingalls/NASA via Getty Images)

RKLB Vs ASTS: Bestselling Investing Author Picks The ‘Lottery Ticket’ With Better Odds — But SpaceX Is The ‘Top Dog’

Leverage Shares 2X Long ASTS Daily ETF

Tidal Trust II - Defiance Daily Target 2X Short ASTS ETF

AST SpaceMobile Inc

Tradr 2X Long ASTS Daily ETF

Tidal Trust II - Defiance Daily Target 2X Long ASTS ETF

Tema Space Innovators ETF

Rocket Lab USA Inc

Defiance Daily Target 2X Long RKLB ETF

SpaceX

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$3.33
Prev Close	$3.26
Open	$3.10
Dividend Yield	N/A
50-Day Moving Average	$7.80
Beta	N/A
Avg. Volume	40,775.99
PE Ratio	N/A

52-Week High	$21.53
52-Week Low	$3.00
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

ASTG Fundamentals